Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Media
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsShortsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Radiation Oncology|
Surgery
Advertisement

Andrea Sporchia

Advertisement

Articles by Andrea Sporchia

TIP113 HERTHENA-PanTumor01 (NCT06172478): Expansion of a Global Phase 2 Trial of HER3-DXd in Patients With Advanced/Metastatic HR+/HER2− Breast Cancer

ByFunda Meric-Bernstam, MD,Christos Fountzilas,Izuma Nakayama,Takahiro Kogawa,Tomohiro Nishina,Thomas Powles, MBBS, MCRP, MD,Jin Won Kim,Yen-Yang Chen,Francois Ghiringhelli,Valentina Gambardella,James W. Smithy,Jérome Fayette,Fan Jin,Y.K. Chang,Kendall Sullivan,Sue Yueh,Ajlan Atasoy,Andrea Sporchia,Ragini Kudchadkar, MD,Hidetoshi Hayashi
May 14th 2026

82 Efficacy, Safety, and Biomarker Analysis of ICARUS-BREAST01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HR+/HER2– Advanced Breast Cancer

ByBarbara Pistilli,Livia Pierotti,Magali Lacroix-Triki,Cecile Vicier,Jean-Sebastien Frenel,Véronique D’Hondt,Florence Dalenc,Thomas Bachelot,Agnes Ducoulombier,Marc-Antoine Benderra,Delphine Loirat,Didier Mayeur,Ghada B. Nachabeh,Andrea Sporchia,Fumitaka Suto,Stefan Michiels,Noemie Corcos,Fernanda Mosele,Fabrice André, Guillaime Montagnac
April 28th 2025
Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on CancerNetwork

    1

    Investigational Radioenhancer Shows Feasibility in Stage III NSCLC

    2

    Subcutaneous Isatuximab May Optimize Multiple Myeloma Treatment Protocols

    3

    Mechanistic and Translational Insights of CARv3-TEAM-E in Glioblastoma

    4

    Toxicity From CD19, BCMA Therapy May Inform B-Cell Malignancy Surveillance

    5

    104 KATSIS-1: Randomized Phase 3 Trial Evaluating KAT6 Inhibitor PF-07248144 (prifetrastat) Plus Fulvestrant in HR+HER2− Advanced/Metastatic Breast Cancer After Progression on CDK4/6 Inhibitor-Based Therapy

    • About
    • Advertise
    • CureToday.com
    • OncLive.com
    • OncNursingNews.com
    • TargetedOnc.com
    • Editorial
    • Contact
    • Terms and Conditions
    • Privacy
    • Do Not Sell My Personal Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us